SB 211475

Subscribe to Selected New Research on SB 211475

2 relevant articles (1 outcomes, 1 trials/studies) found for this Bio-Agent

Description: a carvedilol metabolite; structure given in first source

Also Known As:

(4-(2-hydroxy-3-((2-(2-methoxy-phenoxy)ethyl)amino)propoxyl)-9H-carbazol-3-ol); SB-211475

Relationship Network

Bio-Agent Context: Research Results

Related Diseases

1.	Shock 01/01/1998 - "At doses of 0.5 mg kg(-1) and 1.0 mg kg(-1), SB 211475 exerted significant anti-shock and endothelial protective effects, characterized by prolonged survival times, increased survival rates, attenuated increases in tissue myeloperoxidase activity and haematocrits, and preserved endothelium-dependent vasorelaxation" 01/01/1998 - "The present experiment was designed to evaluate the effects of SB 211475, a hydroxylated metabolite of the new beta-adrenoceptor antagonist, carvedilol, on rat splanchnic ischaemia (SI, 60 min) and reperfusion(R)-induced shock and tissue injury" Get all the results and reference details, order at left...
2.	Myocardial Reperfusion Injury 09/04/1998 - "The aim of this study was to investigate the effect of SB 211475, a metabolite of carvedilol with weak alpha1-adrenoceptor antagonism and antioxidant effect, on myocardial reperfusion injury and infarct size in anesthetized rabbits" Get all the results and reference details, order at left...
3.	Reperfusion Injury 09/04/1998 - "In conclusion, SB 211475 in the two highest doses reduced infarct size by protecting from reperfusion injury, possibly by reduced neutrophil accumulation" 09/04/1998 - "SB 211475, a metabolite of carvedilol, reduces infarct size after myocardial ischemic and reperfusion injury in rabbits." Get all the results and reference details, order at left...
4.	Inflammation 09/04/1998 - "Carvedilol and SB 211475 1.0 and 3.0 mg/kg reduced myeloperoxidase activity to the same extent, indicative of reduced inflammation" Get all the results and reference details, order at left...
4 Diseases and 2 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Peroxidase (Myeloperoxidase)
2.	carvedilol (Coreg)
2 Drugs and Important Bio-Agents and 2 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>